Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Depreciation and Depletion (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Depreciation and Depletion for 5 consecutive years, with $121000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation and Depletion rose 37.5% year-over-year to $121000.0, compared with a TTM value of $196000.0 through Dec 2025, down 56.25%, and an annual FY2025 reading of $196000.0, down 56.25% over the prior year.
  • Depreciation and Depletion was $121000.0 for Q4 2025 at Kiniksa Pharmaceuticals International, up from $27000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $416000.0 in Q2 2021 and bottomed at $13000.0 in Q2 2025.
  • Average Depreciation and Depletion over 5 years is $219400.0, with a median of $262500.0 recorded in 2023.
  • The sharpest move saw Depreciation and Depletion soared 64.97% in 2023, then crashed 89.08% in 2025.
  • Year by year, Depreciation and Depletion stood at $376000.0 in 2021, then decreased by 21.81% to $294000.0 in 2022, then fell by 19.73% to $236000.0 in 2023, then plummeted by 62.71% to $88000.0 in 2024, then soared by 37.5% to $121000.0 in 2025.
  • Business Quant data shows Depreciation and Depletion for KNSA at $121000.0 in Q4 2025, $27000.0 in Q3 2025, and $13000.0 in Q2 2025.